P21 side effects and risks

Reported side effects

• Sleepiness or overstimulated fatigue: One nasal spray user described alternating stimulation and sleepiness; no incidence estimate., moderate. Avoid driving when sleepy and review new symptoms. The report included existing sleep disorders. (source)
• Allergy or infection related to the product: General unapproved product risk; no measured P021 event rate., serious. Breathing problems or spreading injection-site infection need urgent care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse or fainting after exposure.: Call emergency services now. These can be signs of anaphylaxis.
• A hot, painful, spreading red injection site, especially with fever or feeling very ill.: Seek urgent medical care. Confusion, fainting or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precautionary block: no human pregnancy safety data. Prenatal mouse experiments do not establish fetal safety.
• breastfeeding: Precautionary block: milk transfer and infant safety have not been studied in humans.
• tryingToConceive: Precautionary block: human fertility and early-pregnancy effects are unknown.
• under18: Precautionary block: no human pediatric dose or developmental safety study identified.
• activeCancer: Growth-related signaling changes occur in lab models. Cancer safety in people is unknown; this is a precaution, not proof of cancer risk.
• cancerHistory: No human recurrence or cancer-safety data; discuss experimental growth-signaling compounds with the treating clinician.
• seizureDisorder: No human seizure safety data. The CDKL5 mouse study does not establish safety or benefit for human epilepsy.
• psychiatricCondition: No human mood or psychiatric safety study. Reports of stimulation and sleepiness warrant review.
• kidneyDisease: Human clearance and dose adjustment in kidney disease are unknown.
• liverDisease: Human metabolism and dose adjustment in liver disease are unknown.
• testedAthlete: Unapproved pharmacological substances fall under the 2026 prohibited-list rules; growth-factor rules may also apply.

Interactions

• Other nootropics, peptides and sedating substances: P021 interaction studies are absent. Stacking may add unpredictable effects; sleepiness is reported, but a specific drug interaction is unproven.

Product quality risks

• General peptide warnings describe wrong ingredients, wrong amounts and microbial or solvent contamination. No independent market survey of this compound was located.
• A purity percentage cannot establish dose, identity, sterility or clinical safety.
• Research-use labeling does not mean a product meets medicine quality standards.